Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis

Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis

2019 J Dermatol

Igarashi, A. | Fujita, H. | Arima, K. | Inoue, T. | Dorey, J. | Fukushima, A. | Taguchi, Y. | Volume: 46, Issue: 8, Pages: 652-661, Adult, Ambulatory Care/statistics & numerical data, *Cost of Illness, Cyclosporine/therapeutic use, Databases, Factual/statistics & numerical data, Dermatitis, Atopic/economics/*therapy, Dermatologic Agents/*therapeutic use, Drug Prescriptions/statistics & numerical data, Female, Glucocorticoids/therapeutic use, Hospitalization/statistics & numerical data, Humans, Japan, Male, Middle Aged, Patient Acceptance of Health Care/*statistics & numerical data, Phototherapy/*statistics & numerical data, Retrospective Studies, Young Adult, atopic dermatitis, claim database, health-care resource use, treatment patterns, study. A. I. received consultancy fees from AbbVie Inc., Eli Lilly Japan K.K.,, Novartis Pharma K.K., Maruho Co. Ltd, Torii Pharmaceutical Co. Ltd., Japan Tobacco, Inc. and Sanofi K.K., including fees for this study. H. F., K. A., T. I. and Y. T., are employees of Sanofi K.K. J. D. and A. F. are employees of Creativ‐Ceutical. The, authors were responsible for all content and editorial decisions, and received no, honoraria related to the development of this publication.,

The real-world evidence on the profiles of patients suffering from atopic dermatitis (AD) in Japan is sparse. A retrospective claim database analysis was conducted to estimate the health-care resource use (HCRU) and current AD treatment. Data from October 2013 to September 2016 were extracted from the JMDC (Tokyo, Japan) claims database. HCRU was assessed by a comparison of AD patients and matched non-AD controls. A multivariate analysis was performed to estimate HCRU attributable to AD. AD patients (n = 39 893) have more claims of certain diagnoses such as rhinitis, viral and fungal infections, sleep disorders and conjunctivitis as well as higher HCRU (outpatient visits, prescriptions of AD-related and non-AD-related medications, phototherapy, laboratory tests) than matched non-AD controls (n = 39 893). Treatment pattern analysis included treatment-naive patients (n = 8478) and previously treated AD patients (n = 30 109). Approximately 20% of previously treated patients were on the continuous systemic treatment during 18-month follow up. Systemic corticosteroids were the most frequently used systemic treatments. Oral cyclosporin was less frequently used in both groups, but for the longest duration. Almost half of previously treated patients with oral cyclosporin continued treatment for more than 3 months. In conclusion, HCRU was higher in AD patients than non-AD controls, indicating a high burden of the disease imposed on AD patients. Continuous administration of systemic treatment, such as oral cyclosporin, systemic corticosteroids and phototherapy, observed in AD patients sheds light on the difficulties of managing AD in Japanese clinical practise.

https://www.doi.org/10.1111/1346-8138.14947